Replies to post #194060 on Biotech Values

[DewDiligence]

OCRX—…95 enrolled patients [in the STOP-HE trial] must have been seen as a positive number.

I would say it’s neutral rather than positive. OCRX said it had “over 70” patients enrolled as of 5/3/15 (the date of the 1Q15 CC), so the delta to “over 95” enrolled as of yesterday is 25 patients in three months. That’s actually a little slower than the guidance of about 10 patients per month.

[DewDiligence]

OCRX—STOP-HE trial has surpassed 50% enrollment (i.e. >115 of 230); cash balance at 9/30/15 was $47.9M; end-2015 cash guidance is “low end of $21-25M range”:

http://www.sec.gov/Archives/edgar/data/1274644/000127464415000063/oceratherapeuticsreportsth.htm

The updated STOP-HE enrollment of >115 patients is about 20 patients more than the >95 patients who were enrolled as of 8/3/15 (http://www.sec.gov/Archives/edgar/data/1274644/000127464415000040/oceratherapeuticsreportsse.htm ); this represents an enrollment rate of about 7 patients per month during the past three months. Thus, the enrollment rate will have to pick up for OCRX to meet its guidance to complete enrollment in 2H16.

No CC.